283. 後天性赤芽球癆 Acquired pure red cell aplasia Clinical trials / Disease details
臨床試験数 : 19 / 薬物数 : 36 - (DrugBank : 23) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00314795 (ClinicalTrials.gov) | April 6, 2006 | 13/4/2006 | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease | Anemia;Chronic Kidney Disease;Chronic Renal Failure;Pure Red Cell Aplasia | Drug: Peginesatide | Takeda | NULL | Completed | 18 Years | N/A | All | 22 | Phase 2 | France;Germany;United Kingdom |
| 2 | EUCTR2005-004944-30-DE (EUCTR) | 08/03/2006 | 20/12/2005 | A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia. | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematide™) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 | Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide | Takeda Development Centre Europe Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Germany;United Kingdom | ||
| 3 | EUCTR2005-004944-30-GB (EUCTR) | 23/02/2006 | 09/12/2005 | A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia. | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 | Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide | Takeda Development Centre Europe Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Germany;United Kingdom |